+ All Categories
Home > Documents > Cell-free DNA Quality and Quantity Assessment – A Method ... · Cell-free DNA Quality and...

Cell-free DNA Quality and Quantity Assessment – A Method ... · Cell-free DNA Quality and...

Date post: 22-Sep-2020
Category:
Upload: others
View: 0 times
Download: 0 times
Share this document with a friend
1
Cell-free DNA Quality and Quantity Assessment – A Method Comparison 1 Andrea Ullius, 2 Elisa Viering, 2 Eva Graf, and 1 Thorsten Voss 1 PreAnalytiX GmbH, Hombrechtikon, Switzerland; 2 Agilent Technologies, Waldbronn, Germany Introduction Workflow standardization is required for successful use of circulating cell-free DNA (ccfDNA) in cancer research. The European technical specification for isolation of ccfDNA (CEN/TS 16835-3:2015) and future ISO standard focuses on preanalytical factors like preventing cellular DNA release by using blood stabilization tubes and dedicated isolation procedures. Furthermore, accurate determination of ccfDNA quality and quantity is required for downstream analyses like NGS, quantitative or digital PCR (qPCR/dPCR). This research study compares common methods for quality control of ccfDNA from venous whole blood collected and stored for 7 days in EDTA and PAXgene ® Blood ccfDNA Tubes* and processed with manual and automated preparation kits. Methods Blood from eight healthy donors was collected in EDTA (BD) and PAXgene Blood ccfDNA Tubes (PreAnalytiX). Paired tubes were processed directly (T0) or after storage for 7 days (T7d) at 25°C. CcfDNA extraction was performed manually using the QIAamp Circulating Nucleic Acid Kit (QA, QIAGEN) or automated on the QIAsymphony ® instrument (QS) using tube-specific kits and protocols. All 64 samples were analyzed for ccfDNA quality and/or quantity with QC methods based on fluorescence, automated electrophoresis and PCR according to Table 1. Method category Assay Name Instrument Supplier Fluorometric measurement Qubit TM dsDNA HS Assay Kit (10x)* Qubit 2.0 Thermo Fisher Scientific Qubit 1x dsDNA HS Assay Kit* - premixed kit Automated electrophoresis Cell-free DNA ScreenTape assay* 4200 TapeStation System Agilent Technologies qPCR Investigator ® Quantiplex Pro (91 bp amplicon) Rotor-Gene ® Q QIAGEN dPCR 18S rDNA 66 bp (QIAGEN in-house assay) QX200 TM Droplet Digital PCRTM System (QIAGEN)/BioRad Table 1 - Methods used for ccfDNA quality and quantity assessment Results Total ccfDNA quantification Manual and automated ccfDNA extraction methods enable high workflow consistency and comparable ccfDNA yields quantified with the TapeStation system, Qubit 1x, Quantiplex Pro and 18S ddPCR assays Storage of unstabilized blood in EDTA tubes for 7 days at 25°C results in up to 80-fold increase of total DNA in plasma Stabilization for consistent ccfDNA quantification is needed Electrophoretic and PCR-based DNA quantification methods show comparable results when analyzing low and high ccfDNA concentrations Fluorometric assays (Qubit 1x and 10x) show higher variation when measuring ccfDNA. For high concentration ranges both Qubit assays have limited measuring capacity TapeStation Qubit 10x Qubit 1x Quantiplex Pro 18S ddPCR 150 100 50 0 ng DNA/eluate PAXgene T0 QS (automated) EDTA T0 QS (automated) PAXgene T0 QA (manual) EDTA T0 QA (manual) A Four of five investigated quantification assays resulted in comparable yield quantification Yield of total ccfDNA Manual/automated extraction methods TapeStation Qubit 10x Qubit 1x Quantiplex Pro 18S ddPCR 50000 40000 30000 20000 10000 5000 4000 3000 2000 1000 0 pg DNA/μl eluate B ccfDNA from blood stored for 7 days in PAXgene tubes shows no significant difference in concentration, while ccfDNA concentration from blood stored in EDTA tubes is highly elevated. Concentration of total ccfDNA Stored whole blood PAXgene T7d EDTA T7d PAXgene T0 EDTA T0 Comparison of quantification methods for ccfDNA samples of plasma from stored and unstored whole venous blood collected in EDTA and PAXgene Blood ccfDNA Tubes. (A) Total DNA yield quantification (ng DNA/eluate) of ccfDNA eluates isolated with QIAamp (QA) and QIAsymphony (QS) from unstored EDTA and PAXgene samples (T0), n = 8. (B) Concentration of total ccfDNA (pg DNA/µl eluate) extracted from plasma of unstored (T0) and stored (T7d) EDTA and PAXgene samples using QIAamp, n = 8. Data presented as box plots with median and upper and lower quartiles, whiskers with maximum 1.5 interquartile ranges (Tukey method). Outliers are shown as dots, extremes were excluded from analysis. ccfDNA qualification and quantification PAXgene Blood ccfDNA stabilization ensures reliable and consistent ccfDNA quantification and qualification of unstored and stored blood samples Blood storage in EDTA tubes leads to gDNA release resulting in an increase of high molecular weight (HMW) DNA and ccfDNA (degraded gDNA) concentration The new Cell-free DNA ScreenTape assay enables total quantification as well as quantification of a predefined cfDNA region (from 50 to 700 bp) without an upper marker 25000 8000 7000 6000 5000 4000 Sample Intensity [Normalized FU] pg DNA/μl eluate Size (bp) 3000 2000 1000 0 35 50 75 100 150 200 300 400 500 600 700 1000 Size [bp] Size [bp] 200 190 180 170 160 20000 15000 10000 5000 1500 1000 500 0 Lower marker Lower marker Detail cfDNA region (50–700 bp) HMW DNA DNA concentration of cfDNA region (preset region: 50–700 bp) Mononucleosome peak A B HMW DNA C T0 EDTA cfDNA region (50–700 bp) Mononucleosome peak D T0 T7d T7d PAXgene T0 EDTA T0 T7d T7d PAXgene Fragment size mononucleosome peak (in bp) PAXgene T7d EDTA T7d PAXgene T0 EDTA T0 500 400 300 200 100 0 35 50 75 100 150 200 300 400 500 600 700 1000 ccfDNA qualification and region quantfication on the TapeStation system (TS) using the Cell-free DNA ScreenTape assay (A) Overlay of ccfDNA electropherogram profiles from one exemplary donor. Quantification of ccfDNA is evaluated by the assay using a pre-set region from 50–700 bp. Indicated are the lower marker, mononucleosomal peak and HMW DNA. (B) Detail of indicated region from figure A. (C) ccfDNA concentration in the pre-set region of 50–700 bp (in pg DNA/µl eluate), n = 8. (D) Main peak size of mononucleosomal peak (in bp) as evaluated by the TapeStation Analysis software (n = 8). Data presented as box plots with median and upper and lower quartiles, whiskers with maximum 1.5 interquartile ranges (Tukey method). Study Design Conclusions The PAXgene Blood ccfDNA workflow using manual or automated ccfDNA extraction is compatible with quantification instruments including Qubit and TapeStation as well as PCR-based methods resulting in comparable yield quantification across different methods The yield of smaller ccfDNA fragments (50–700 bp) and ccfDNA fragment size is consistent in plasma from blood stored for 7 days in PAXgene Blood ccfDNA Tubes and comparable to EDTA T0 (control). It can be analyzed with the new Cell-free DNA ScreenTape assay The release of genomic DNA in EDTA tubes (as HMW and cell-free DNA) over time indicates the need for stabilization of blood in PAXgene Blood ccfDNA Tubes and an accurate quantification method for optimal workflow control Disclaimer *For Research Use Only. Not for use in diagnostic procedures. For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN or PreAnalytiX kit handbook or user manual. QIAGEN and PreAnalytiX kit handbooks and user manuals are available at www.qiagen.com or www.preanalytix.com or can be requested from QIAGEN Technical Services or your local distributor. Trademarks are the property of their respective owners. © 2019 PreAnalytiX GmbH. PreAnalytiX, the PreAnalytiX Logo and all other trademarks are property of PreAnalytiX GmbH, Hombrechtikon, CH. ccfDNA QC workflow Blood collection Sample storage + plasma separation ccfDNA extraction Sample QC PAXgene Blood ccfDNA Tube Qubit 2.0 Rotor-Gene Q Droplet Digital PCR Quantification + Qualification RFU 5000 4000 3000 2000 1000 0 0 10 20 30 40 Cycles 4200 TapeStation System QIAsymphony instrument QIAamp Circulating Nucleic Acid Kit BD Vacutainer ® K 2 EDTA Tube
Transcript
Page 1: Cell-free DNA Quality and Quantity Assessment – A Method ... · Cell-free DNA Quality and Quantity Assessment – A Method Comparison 1Andrea Ullius, 2Elisa Viering, 2Eva Graf,

Cell-free DNA Quality and Quantity Assessment – A Method Comparison 1Andrea Ullius, 2Elisa Viering, 2Eva Graf, and 1Thorsten Voss1PreAnalytiX GmbH, Hombrechtikon, Switzerland; 2Agilent Technologies, Waldbronn, Germany

IntroductionWorkflow standardization is required for successful use of circulating cell-free DNA (ccfDNA) in cancer research. The European technical specification for isolation of ccfDNA (CEN/TS 16835-3:2015) and future ISO standard focuses on preanalytical factors like preventing cellular DNA release by using blood stabilization tubes and dedicated isolation procedures. Furthermore, accurate determination of ccfDNA quality and quantity is required for downstream analyses like NGS, quantitative or digital PCR (qPCR/dPCR).

This research study compares common methods for quality control of ccfDNA from venous whole blood collected and stored for 7 days in EDTA and PAXgene® Blood ccfDNA Tubes* and processed with manual and automated preparation kits.

MethodsBlood from eight healthy donors was collected in EDTA (BD) and PAXgene Blood ccfDNA Tubes† (PreAnalytiX). Paired tubes were processed directly (T0) or after storage for 7 days (T7d) at 25°C. CcfDNA extraction was performed manually using the QIAamp Circulating Nucleic Acid Kit (QA, QIAGEN) or automated on the QIAsymphony® instrument (QS) using tube-specific kits and protocols. All 64 samples were analyzed for ccfDNA quality and/or quantity with QC methods based on fluorescence, automated electrophoresis and PCR according to Table 1.

Method category Assay Name Instrument Supplier

Fluorometric measurement

QubitTM dsDNA HS Assay Kit (10x)*

Qubit 2.0 Thermo Fisher ScientificQubit 1x dsDNA HS

Assay Kit* - premixed kit

Automated electrophoresis

Cell-free DNA ScreenTape assay*

4200 TapeStation System Agilent Technologies

qPCRInvestigator®

Quantiplex Pro†

(91 bp amplicon)Rotor-Gene® Q QIAGEN

dPCR18S rDNA 66 bp

(QIAGEN in-house assay)QX200TM Droplet

Digital PCRTM System(QIAGEN)/BioRad

Table 1 - Methods used for ccfDNA quality and quantity assessment

ResultsTotal ccfDNA quantification

• Manual and automated ccfDNA extraction methods enable high workflow consistency and comparable ccfDNA yields quantified with the TapeStation system, Qubit 1x, Quantiplex Pro and 18S ddPCR assays

• Storage of unstabilized blood in EDTA tubes for 7 days at 25°C results in up to 80-fold increase of total DNA in plasma Stabilization for consistent ccfDNA quantification is needed

• Electrophoretic and PCR-based DNA quantification methods show comparable results when analyzing low and high ccfDNA concentrations

• Fluorometric assays (Qubit 1x and 10x) show higher variation when measuring ccfDNA. For high concentration ranges both Qubit assays have limited measuring capacity

TapeStation Qubit 10x Qubit 1x Quantiplex Pro 18S ddPCR

150

100

50

0

ng D

NA

/elu

ate

PAXgene T0 QS (automated)

EDTA T0 QS (automated)PAXgene T0 QA (manual)

EDTA T0 QA (manual)A

Four of five investigated quantification assays resulted in comparable yield quantification

Yield of total ccfDNAManual/automated extraction methods

TapeStation Qubit 10x Qubit 1x Quantiplex Pro 18S ddPCR

5000040000300002000010000

50004000300020001000

0

pg D

NA

/μl e

luat

e

B

ccfDNA from blood stored for 7 days in PAXgene tubes shows no significant difference in concentration, while ccfDNA concentration from blood stored in EDTA tubes is highly elevated.

Concentration of total ccfDNAStored whole blood

PAXgene T7d

EDTA T7dPAXgene T0

EDTA T0

Comparison of quantification methods for ccfDNA samples of plasma from stored and unstored whole venous blood collected in EDTA and PAXgene Blood ccfDNA Tubes. (A) Total DNA yield quantification (ng DNA/eluate) of ccfDNA eluates isolated with QIAamp (QA) and QIAsymphony (QS) from unstored EDTA and PAXgene samples (T0), n = 8. (B) Concentration of total ccfDNA (pg DNA/µl eluate) extracted from plasma of unstored (T0) and stored (T7d) EDTA and PAXgene samples using QIAamp, n = 8. Data presented as box plots with median and upper and lower quartiles, whiskers with maximum 1.5 interquartile ranges (Tukey method). Outliers are shown as dots, extremes were excluded from analysis.

ccfDNA qualification and quantification

• PAXgene Blood ccfDNA stabilization ensures reliable and consistent ccfDNA quantification and qualification of unstored and stored blood samples

• Blood storage in EDTA tubes leads to gDNA release resulting in an increase of high molecular weight (HMW) DNA and ccfDNA (degraded gDNA) concentration

• The new Cell-free DNA ScreenTape assay enables total quantification as well as quantification of a predefined cfDNA region (from 50 to 700 bp) without an upper marker

25000

8000

7000

6000

5000

4000

Sam

ple

Inte

nsity

[Nor

mal

ized

FU

] p

g D

NA

/μl e

luat

e

Size

(bp)

3000

2000

1000

0

35 50 75 100

150

200

300

400

500

600

700

1000

Size[bp]

Size[bp]

200

190

180

170

160

200001500010000

5000

1500

1000

500

0

Lower marker

Lower marker

Detail

cfDNA region (50–700 bp) HMW DNA

DNA concentration of cfDNA region(preset region: 50–700 bp)

Mononucleosome peak

A B

HMW DNA

C

T0

EDTA

cfDNA region (50–700 bp)

Mononucleosome peak

D

T0 T7dT7d

PAXgene

T0

EDTA

T0 T7dT7d

PAXgene

Fragment size mononucleosome peak(in bp)

PAXgene T7dEDTA T7d PAXgene T0EDTA T0

500

400

300

200

100

0

35 50 75 100

150

200

300

400

500

600

700

1000

ccfDNA qualification and region quantfication on the TapeStation system (TS) using the Cell-free DNA ScreenTape assay

(A) Overlay of ccfDNA electropherogram profiles from one exemplary donor. Quantification of ccfDNA is evaluated by the assay using a pre-set region from 50–700 bp. Indicated are the lower marker, mononucleosomal peak and HMW DNA. (B) Detail of indicated region from figure A. (C) ccfDNA concentration in the pre-set region of 50–700 bp (in pg DNA/µl eluate), n = 8. (D) Main peak size of mononucleosomal peak (in bp) as evaluated by the TapeStation Analysis software (n = 8). Data presented as box plots with median and upper and lower quartiles, whiskers with maximum 1.5 interquartile ranges (Tukey method).

Study Design

Conclusions• The PAXgene Blood ccfDNA workflow using manual or automated ccfDNA extraction is compatible with quantification

instruments including Qubit and TapeStation as well as PCR-based methods resulting in comparable yield quantification across different methods

• The yield of smaller ccfDNA fragments (50–700 bp) and ccfDNA fragment size is consistent in plasma from blood stored for 7 days in PAXgene Blood ccfDNA Tubes and comparable to EDTA T0 (control). It can be analyzed with the new Cell-free DNA ScreenTape assay

• The release of genomic DNA in EDTA tubes (as HMW and cell-free DNA) over time indicates the need for stabilization of blood in PAXgene Blood ccfDNA Tubes and an accurate quantification method for optimal workflow control

Disclaimer *For Research Use Only. Not for use in diagnostic procedures.†For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN or PreAnalytiX kit handbook or user manual. QIAGEN and PreAnalytiX kit handbooks and user manuals are available at www.qiagen.com or www.preanalytix.com or can be requested from QIAGEN Technical Services or your local distributor.

Trademarks are the property of their respective owners.

© 2019 PreAnalytiX GmbH. PreAnalytiX, the PreAnalytiX Logo and all other trademarks are property of PreAnalytiX GmbH, Hombrechtikon, CH.

ccfDNA QC workflow

Bloodcollection

Samplestorage

+plasma

separation

ccfDNAextraction

SampleQC

PAXgene Blood ccfDNA Tube

Qubit 2.0

Rotor-Gene Q

Droplet Digital PCR

Quantification + Qualification

RFU50004000300020001000

00 10 20 30 40

Cycles

4200 TapeStation SystemQIAsymphony instrument

QIAamp Circulating Nucleic Acid Kit

BD Vacutainer® K2EDTA Tube

Recommended